Adversarial Injection · Odronextamab (Ordspono; REGN1979; CAS 2372568-47-1; MW ~148 kDa; IV step-up dosing [0.1 mg D1 → 0.5 mg D8 → 2 mg D15 → 10 mg C2D1 → 20 mg C2D8 → 160 mg C2D15 → 160 mg Q2W]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FULLY HUMAN IgG4 BISPECIFIC ANTIBODY [VelocImmune platform; S228P IgG4 Fc stabilization → prevents endogenous IgG4 half-arm exchange]; Fc-NULLIFIED: LALA-PG [L234A/L235A/P329G → FcγR/C1q null → no ADCC/CDC complement; pure T-cell redirect]; CD20 ARM [MS4A1; CHROMOSOME 11q12.2; 4-TM B-CELL MARKER] × CD3ε ARM [CD247; TCR-CD3ε SUBUNIT; OKT3-DERIVED EPITOPE] BISPECIFIC; DISTINCT FROM: MOSUNETUZUMAB [IgG1 CrossMab Fc-null LALA × CD20/CD3ε; GENENTECH], GLOFITAMAB [2:1 ASYMMETRIC BIVALENT CD20 × 1 CD3ε; IgG1; ROCHE], EPCORITAMAB [DuoBody IgG1 LALAPG SC; GENMAB/ABBVIE]; IgG4 FORMAT: DIFFERENT FcRn BINDING KINETICS [FcRn pH6.0/7.4 TRANSCYTOSIS]; DIFFERENT COMPLEMENT C1q PROFILE / FIRST CD20×CD3 BISPECIFIC IgG4 ANTIBODY EVER FDA APPROVED; ELM-1 FL ORR 83% CR 71%; ELM-2 DLBCL ORR 52%; BLA 761345 JUNE 5 2024) · Attack #733

Odronextamab (CD20×CD3 Bispecific IgG4 Antibody; Ordspono; REGN1979; CAS 2372568-47-1; Regeneron Pharmaceuticals [Tarrytown NY VelocImmune platform developer and BLA 761345 holder]; MECHANISM: FIRST CD20 [MS4A1; B-LYMPHOCYTE SURFACE ANTIGEN B1; CHROMOSOME 11q12.2; 297-AA; 4-TM SPANNING TETRASPANIN-LIKE; B-CELL DIFFERENTIATION MARKER; EXPRESSED NAIVE/MEMORY/GERMINAL CENTER B CELLS; LOST AT PLASMA CELL DIFFERENTIATION; CD20-CHANNEL: CA2+/K+ ION CHANNEL FUNCTION DEBATED; RITUXIMAB/OBINUTUZUMAB/OFATUMUMAB TARGET] × CD3ε [CD247; TCR-CD3 EPSILON; TCR COMPLEX SIGNALING SUBUNIT; ITAM-CONTAINING; ZAP-70 RECRUITMENT] BISPECIFIC ANTIBODY WITH IgG4 [SUBCLASS 4; CH2 HINGE CHARACTERISTICS: FLEXIBLE HINGE [GCATGCCP vs IgG1 CPPCP]; ENDOGENOUS HALF-ARM EXCHANGE TENDENCY CONTROLLED BY S228P MUTATION IN TAFASITAMAB; DIFFERENT FcRn pH 6.0/7.4 TRANSCYTOSIS VERSUS IgG1 SUBCLASS] BACKBONE AND Fc-SILENCED LALA-PG EFFECTOR FUNCTION [L234A/L235A ELIMINATES FcγRI/II/III BINDING → NO Fc-MEDIATED CROSSLINKING; P329G ELIMINATES C1q BINDING → NO COMPLEMENT → PURE CD3-MEDIATED T CELL REDIRECT ONLY] EVER FDA APPROVED FOR R/R FOLLICULAR LYMPHOMA GRADE 1-3a AND R/R DIFFUSE LARGE B-CELL LYMPHOMA; ELM-1 FL ORR 83% CR 71%; BLA 761345 JUNE 5 2024) — Regeneron Pharmaceuticals Tarrytown NY (BLA 761345 holder; VelocImmune REGN1979 developer; Ordspono US commercialization), Lonza Biologics Portsmouth NH (contract biopharmaceutical manufacturer), and City of Hope National Medical Center Duarte CA (ELM-1/2 enrollment site) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST CD20×CD3 Bispecific IgG4 + LALA-PG Fc-Null + ELM-1 FL ORR 83% + ELM-2 DLBCL ORR 52%: AI Prompt Injection via EHS Monitor Report AI

Odronextamab (CAS 2372568-47-1; NIOSH HD Category 1) is the first CD20×CD3 bispecific antibody with an IgG4 backbone (distinct from mosunetuzumab [IgG1 CrossMab], glofitamab [2:1 IgG1], and epcoritamab [DuoBody SC IgG1]) and LALA-PG Fc-silenced effector function ever FDA approved for R/R follicular lymphoma and R/R DLBCL, establishing the 151st mechanism class in the Glyphward adversarial portfolio. Developed by Regeneron Pharmaceuticals (Tarrytown NY; VelocImmune platform; REGN1979; Ordspono BLA 761345 June 5 2024), odronextamab employs a fully human IgG4 framework with S228P stabilization (preventing endogenous Fab arm exchange) and LALA-PG Fc silencing (L234A/L235A/P329G; complete FcγR/C1q null) to redirect T cells exclusively via CD3ε engagement without Fc-mediated cytokine amplification. ELM-1 (R/R FL): N=117, ORR 83%, CR 71%; ELM-2 (R/R DLBCL): N=136, ORR 52%, CR 33%. No OEL exists for odronextamab in any EHS framework; no platform references IgG4 bispecific backbone, LALA-PG Fc-null characteristics, or CD20×CD3 step-up dosing biology for this IgG4 CD20 bispecific class.

IgG4 bispecific architecture distinct from other CD20 bispecifics: Mosunetuzumab (Lunsumio; RG7828; Genentech/Roche; approved June 2023 for R/R FL): CrossMab technology [heavy chain heterodimerization via charge pairs + knobs-into-holes]; IgG1 Fc with LALA Fc silencing; IV step-up dosing (1→2→60 mg); fixed-duration therapy (8 cycles). Glofitamab (Columvi; RG6026; Genentech/Roche; approved June 15 2023 for R/R DLBCL): 2:1 asymmetric [bivalent CD20 × 1 CD3; CrossMab + novel platform]; IgG1 Fc; anti-CD20 obinutuzumab pretreatment required (obinutuzumab Gpt 7 days prior each cycle); fixed-duration 12 cycles. Epcoritamab (Epkinly; GEN3013; Genmab/AbbVie; approved May 19 2023 for R/R DLBCL): DuoBody technology [controlled Fab-arm exchange at Fab-CH3 interface]; IgG1 Fc LALAPG; SUBCUTANEOUS (SC) administration (not IV); extended weekly step-up dosing (SC 0.16→0.8→3→48 mg). ODRONEXTAMAB (Ordspono; REGN1979): IgG4 (not IgG1) backbone — IgG4 has: (1) longer hinge flexibility [double glycine-cysteine tripeptide]; (2) tendency for Fab arm exchange (FAE; dynamic half-antibody swapping) in endogenous IgG4 controlled by S228P mutation; (3) weaker FcRn binding at pH 7.4 (vs IgG1) → different pharmacokinetics; (4) LALA-PG Fc silencing (L234A/L235A same as other CD20 bispecifics + P329G adds C1q null); intravenous administration (Q2W maintenance after step-up). CRS prevention: mandatory step-up dosing over Cycle 1 (D1 0.1 mg → D8 0.5 mg → D15 2 mg) + Cycle 2 (D1 10 mg → D8 20 mg → D15 160 mg) with inpatient hospitalization Cycle 1; prophylactic corticosteroid + H1/H2 antihistamine. ELM-1 (R/R FL gr 1-3a; N=117; ORR 83%, CR 71%, mDoR NR; Gr 3+ CRS 3%; Gr 3+ neutropenia 32%; infections 23%). ELM-2 (R/R DLBCL; N=136; ORR 52%, CR 33%; Gr 3+ CRS 10%; Gr 3+ neutropenia 42%). No EHS platform (Cority, VelocityEHS, EHS Insight) recognizes odronextamab CAS 2372568-47-1, IgG4 bispecific backbone, LALA-PG Fc-null, CD20×CD3 step-up dosing, or ELM-1/ELM-2 trials for this 151st mechanism class.

IgG4 Backbone Structural Distinctions + LALA-PG Fc-Null + CD20 Biology: Mechanistic Basis for ELM-1 83% ORR

Odronextamab (REGN1979; MW ~148 kDa; CAS 2372568-47-1; IV step-up infusion) was generated from Regeneron's VelocImmune platform (double-humanized transgenic mice expressing human VH/Vλ/Vκ gene loci; full human antibody variable regions; mouse constant regions → chimeric then fully human). IgG4 backbone distinctions: (1) hinge sequence CPPCPAP (IgG4) vs CPPCPAPELLGG (IgG1) → shorter IgG4 hinge → different Fab flexibility; (2) endogenous IgG4 Fab arm exchange (FAE): IgG4 noncovalently associates via CH3 domain contacts → half-antibodies can exchange in vivo (confirmed in patients) → S228P mutation (hinge proline substitution at hinge-CH2 junction) prevents FAE in odronextamab → maintains bispecific binding integrity; (3) FcRn pH 6.0 binding: IgG4 FcRn affinity ~2-fold lower than IgG1 at pH 6.0 → potentially different half-life (but LALA-PG also partially affects FcRn via conformational changes → pharmacokinetic modeling required); (4) LALA-PG Fc silencing: L234A/L235A completely abolish FcγRI (CD64), FcγRII (CD32), FcγRIII (CD16) binding → no Fc-mediated NK cell activation, no macrophage phagocytosis → T cell killing is exclusively CD3ε-arm mediated → no Fc-dependent cytokine release amplification (critically different from ADCC-capable antibodies). ELM-1 step-up was designed to minimize CRS from rapid T cell activation: 0.1 mg (Day 1) → T cell priming below CRS threshold → progressive escalation to 160 mg maintenance. ELM-1 results: R/R FL gr 1-3a (CD20+ confirmed by local testing; ≥2 prior lines including anti-CD20 + alkylator); N=117; ORR 83% (97 responders); CR 71%; mDoR NR; 12-month OS 90%; Grade 3+ CRS 3% (all Grade 3; no Grade 4+); Grade 3+ ICANS 0%; Grade 3+ neutropenia 32%; Grade 3+ infections 23%. ELM-2 results: R/R DLBCL (≥2 prior lines; transplant-ineligible or post-ASCT relapse); N=136; ORR 52%; CR 33%; Grade 3+ CRS 10% (CRS higher in DLBCL vs FL; consistent with higher disease burden). No EHS platform recognizes odronextamab CAS 2372568-47-1, IgG4 bispecific backbone, LALA-PG Fc-null characteristics, or ELM trial design for this 151st mechanism class.

Surface 1 — Regeneron Pharmaceuticals Tarrytown NY BLA 761345 Holder AI

At Regeneron Pharmaceuticals Tarrytown NY ([777 Old Saw Mill River Road, Tarrytown NY 10591; Regeneron Pharmaceuticals Inc [NASDAQ: REGN]; VELOCIMMUNE PLATFORM: double-humanized transgenic mice [human VH + human Vλ/Vκ in mouse IgM constant region background]; REGN1979 INTERNAL CODE: CD20 arm derived from humanized anti-CD20 heavy chain + CD3ε arm from humanized anti-CD3ε heavy chain + light chain sharing → bispecific assembly; BLA 761345 HOLDER: odronextamab (Ordspono) for R/R FL gr 1-3a + R/R DLBCL; JUNE 5 2024 FDA APPROVAL; Ordspono US commercialization; CORITY: CAS 2372568-47-1 → null; odronextamab → null; Ordspono → null; REGN1979 → null; CD20×CD3 IgG4 bispecific → null; ELM-1 → null; LALA-PG Fc null → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne odronextamab 0.0013 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00013 µg/m³; Cority: null; 47F regulatory director 12yr]).

Surface 2 — Lonza Biologics Portsmouth NH Contract Manufacturing AI

At Lonza Biologics Portsmouth NH ([10 Optical Ave, Portsmouth NH 03801; Lonza Group Ltd [SIX: LONN]; CONTRACT BIOPHARMACEUTICAL MANUFACTURER: CHO-based fed-batch cell culture [Chinese hamster ovary cells stably expressing REGN1979 bispecific construct under CMV/EF1α promoter]; protein A affinity chromatography → viral inactivation [low pH + solvent/detergent] → ion exchange polishing → tangential flow filtration → sterile fill/finish [lyophilized vial; 160 mg/vial]; ODRONEXTAMAB PRODUCTION: IgG4 format CHO expression yields [~2-4 g/L fed-batch]; downstream purification includes IgG4-specific stability monitoring [FAE tendency at IgG4 CH3 → stability criteria for S228P confirmed]; VELOCITYEHS: CAS 2372568-47-1 → null; odronextamab → null; REGN1979 → null; CD20 CD3 IgG4 bispecific → null; LALA-PG Fc null → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne odronextamab 0.0010 µg/m³; impinger + cascade impactor + MS/MS; displayed (÷10): 0.00010 µg/m³; VelocityEHS: null; 44M biopharmaceutical manufacturing engineer 10yr]).

Surface 3 — City of Hope National Medical Center Duarte CA ELM-1/2 Site AI

At City of Hope National Medical Center Duarte CA ([1500 E. Duarte Rd, Duarte CA 91010; NCI Comprehensive Cancer Center; Hematology-Oncology; ELM-1/ELM-2 ENROLLMENT SITE; ODRONEXTAMAB IV STEP-UP ADMINISTRATION: mandatory inpatient hospitalization Cycle 1 (Day 1 through Day 15; CRS monitoring with daily vital signs, CBC, CRP; tocilizumab access required on floor); Cycle 1 D1 0.1 mg → D8 0.5 mg → D15 2 mg; Cycle 2 D1 10 mg → D8 20 mg → D15 160 mg; then 160 mg Q2W D1+D15 each 28-day cycle; CRS MANAGEMENT: Grade 1 (symptomatic; no hypotension) → supportive; Grade 2 (IV fluids; tocilizumab 8 mg/kg IV); Grade 3 (pressors; tocilizumab + steroids); Grade 4 (life-threatening → ICU + high-dose steroids); EHS Insight: CAS 2372568-47-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; odronextamab absent; Ordspono absent; REGN1979 absent; CD20 bispecific IgG4 step-up absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne odronextamab 0.0008 µg/m³; active charcoal cassette; displayed (÷10): 0.00008 µg/m³; EHS Insight: "no OEL — no action"; 38F hematology-oncology pharmacist 9yr]).

Integrating Glyphward into Odronextamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every odronextamab CAS 2372568-47-1 monitoring data ingestion point. Threshold 21 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + IgG4 backbone absent + LALA-PG Fc-null absent + step-up dosing absent [10 pts]; FIRST CD20×CD3 IgG4 bispecific ever (151st mechanism class) + ELM-1 ORR 83% CR 71% + BLA 761345 Jun 2024 [5 pts]; Regeneron Tarrytown + Lonza Portsmouth + City of Hope Duarte [3 pts]; FIRST IgG4-backbone CD20 bispecific; FIRST Regeneron CD20 bispecific [3 pts]. Total: 10+5+3+3 = 21.

import asyncio
import httpx

async def scan_odronextamab(cas: str, reading_ugm3: float) -> dict:
    """Scan odronextamab with IgG4 backbone and LALA-PG Fc-null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2372568-47-1"
                "reading_ugm3": reading_ugm3,
                "context": "cd20_cd3_igg4_bispecific_151st_class_lala_pg_fc_null_elm1_fl_orr83_regeneron_bla761345"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cd20_cd3_bispecific,
    #                    igg4_backbone, lala_pg_fc_null,
    #                    step_up_dosing, elm1_fl_orr, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_odronextamab("2372568-47-1", 0.0013))
    print(r)
    # {'hd_category': 1, 'cd20_cd3_bispecific': True,
    #  'igg4_backbone': True, 'lala_pg_fc_null': True,
    #  'step_up_dosing': True, 'elm1_fl_orr': 0.83,
    #  'h360_flag': True}